<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4494930</article-id><article-id pub-id-type="pmid">25895127</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain><z:uniprot sup="inside" fb="2" ids="P69310,Q865C5,P68197,P19848,Q8SWD4,P69313,P84589,P69317,P62975,P69326">Ubiquitin</z:uniprot> E3 ligase <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> promotes ovarian tumor growth </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Jianguo</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Tinghe</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Lina</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mao</surname><given-names>Ming</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Obstetrics and Gynecology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Lina Hu,</italic><email>cqhulina@126.com</email></corresp></author-notes><pub-date pub-type="collection"><day>20</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>26</day><month>3</month><year>2015</year></pub-date><volume>6</volume><issue>14</issue><fpage>12174</fpage><lpage>12187</lpage><history><date date-type="received"><day>21</day><month>10</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: © 2015 Hu et al.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain><z:uniprot sup="inside" fb="2" ids="P69310,Q865C5,P68197,P19848,Q8SWD4,P69313,P84589,P69317,P62975,P69326">Ubiquitin</z:uniprot> E3 ligase <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> is involved in T cell proliferation and neuronal development. </plain></SENT>
<SENT sid="2" pm="."><plain>We found that expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was higher in ovarian cancer tissues than normal ovarian tissues. </plain></SENT>
<SENT sid="3" pm="."><plain>Silencing <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> decreased cell proliferation, migration, and invasion. </plain></SENT>
<SENT sid="4" pm="."><plain>Ectopic expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> increased cell proliferation, migration and invasion. </plain></SENT>
<SENT sid="5" pm="."><plain>Silencing <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> prevented ovarian cancer growth in mice. </plain></SENT>
<SENT sid="6" pm="."><plain>Silencing <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> inhibited NFkB and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathway. </plain></SENT>
<SENT sid="7" pm="."><plain>In agreement, ectopically expressed <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> activated NFkB and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathways. </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was regulated by miR-101. </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> is oncogenic and a potential target (oncotarget) for ovarian cancer therapy. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>ovarian cancer</kwd><kwd>MARCH7</kwd><kwd>NF-Kb</kwd><kwd>Wnt</kwd><kwd>β-catenin</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="10" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="11" pm="."><plain>The membrane-associated RING-CH (MARCH) proteins belong to the RING finger protein family of E3 <z:uniprot sup="inside" fb="2" ids="P69310,Q865C5,P68197,P19848,Q8SWD4,P69313,P84589,P69317,P62975,P69326">ubiquitin</z:uniprot> ligases, consisting of 11 members in mammals. </plain></SENT>
<SENT sid="12" pm="."><plain>MARCH proteins have numerous cellular functions, which include immune regulation, protein quality control, membrane trafficking, and spermatogenesis [1]. </plain></SENT>
<SENT sid="13" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> is a member of the MARCH family, which consists of approximately 690 amino acids within a single RING finger domain [2]. </plain></SENT>
<SENT sid="14" pm="."><plain>Previous studies have suggested that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> plays an important role in T cell proliferation and neuronal development [3]. </plain></SENT>
<SENT sid="15" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> is expressed in multiple types of cells and tissues, including stem cells and precursor cells [4], suggesting its possible role in cell and tissue differentiation. </plain></SENT>
<SENT sid="16" pm="."><plain>However, little is known about the cellular localization and function of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian carcinoma. </plain></SENT>
</text></p><p><text><SENT sid="17" pm="."><plain>In this study, we have observed an aberrant expression and localization of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer tissues by immunohistochemical analyses. </plain></SENT>
<SENT sid="18" pm="."><plain>Additionally, we have elucidated the functions of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer. </plain></SENT>
<SENT sid="19" pm="."><plain>Our results show that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> participates in the regulation of cytoskeleton re-organization, cellular migration and invasion, cell proliferation, and tumorigenesis in ovarian carcinoma cells. </plain></SENT>
<SENT sid="20" pm="."><plain>At the same time, we found that MARCH 7 could modulate nuclear factor kB (NF-kB) and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathways. </plain></SENT>
<SENT sid="21" pm="."><plain>Further, we identified <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was an authentic target of miR-101. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec id="s2"><title><text><SENT sid="22" pm="."><plain>RESULTS </plain></SENT>
</text></title><sec id="s2_1"><title><text><SENT sid="23" pm="."><plain>Aberrant expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian carcinoma tissues </plain></SENT>
</text></title><p><text><SENT sid="24" pm="."><plain>The expression profile of MARCH 7 in ovarian cancer is not yet fully elucidated. </plain></SENT>
<SENT sid="25" pm="."><plain>We examined the expression pattern of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in normal ovary and ovarian cancer tissue samples using IHC. </plain></SENT>
<SENT sid="26" pm="."><plain>The expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was significantly higher in ovarian carcinoma samples than that in normal ovarian samples (Fig. 1 and Table 1). </plain></SENT>
<SENT sid="27" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was predominantly localized on the plasma membrane, and cytoplasm (Fig. 1A-H). </plain></SENT>
<SENT sid="28" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression was significantly higher in epithelial ovarian cancer samples than that in normal ovary tissues (P &lt; 0.05; Table 1). </plain></SENT>
<SENT sid="29" pm="."><plain>To determine the correlation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression with cancer type and cancer stage, all cancer samples were grouped into histologic types (serous papillary adenocarcinoma, mucinous adenocarcinoma, and endometrioid adenocarcinoma) (Fig. 1A-H). </plain></SENT>
<SENT sid="30" pm="."><plain>The differently expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> between serous adenocarcinoma and other histologic type of the tumor was not significant (P&gt;0.05). </plain></SENT>
<SENT sid="31" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> immunostaining was significantly higher in tumor samples in advanced stages (stage III/IV) as compared to those in the early stages (stage I/II) disease (P &lt; 0.01). </plain></SENT>
<SENT sid="32" pm="."><plain>Further, the staining intensity significantly correlated with the tumor grade (grades 2–3 versus 1, P &lt; 0.01). </plain></SENT>
<SENT sid="33" pm="."><plain>However, the associations between <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression and age were not significant (P &gt; 0.05; Table 1). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title><text><SENT sid="34" pm="."><plain>Association of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression with clinicopathological characteristics in 158 patients of EOC </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="35" pm="."><plain>No. of patients </plain></SENT>
</text></th><th align="left" valign="middle" colspan="2" rowspan="1"><text><SENT sid="36" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="37" pm="."><plain>P value </plain></SENT>
</text></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="38" pm="."><plain>(n=158) </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="39" pm="."><plain>Low no.(%) </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="40" pm="."><plain>High no.(%) </plain></SENT>
</text></th><th align="left" valign="middle" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="41" pm="."><plain>Characteristics </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="42" pm="."><plain>Age(years) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="43" pm="."><plain>&gt;0.5 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="44" pm="."><plain>&lt;50 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="45" pm="."><plain>83 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="46" pm="."><plain>36(43.37%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="47" pm="."><plain>47(56.63%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="48" pm="."><plain>≥50 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain>75 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>35(46.67%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>40(53.33%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>Normal ovarian </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>18(90%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain>2(10%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>&lt;0.05 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>Cancer tissues </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>138 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>79(57.25) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>59(42.75%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>FIGO stage </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>I/II </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>103 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>74(71.84%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>29(28.16%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>III/IV </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>35 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>5(14.29%) </plain></SENT>
</text></td><td align="right" valign="middle" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>30(85.71%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>Grade </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>30 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>23(76.67%) </plain></SENT>
</text></td><td align="right" valign="middle" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>7(23.33%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>36 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>24(66.67%) </plain></SENT>
</text></td><td align="right" valign="middle" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>12(33.33%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>72 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>30(41.67%) </plain></SENT>
</text></td><td align="right" valign="middle" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>42(58.33%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>Grade 2-3 versus 1 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>&lt;0.05 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>Tumor type </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>Serous </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>120 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>67(32.81%) </plain></SENT>
</text></td><td align="right" valign="middle" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>53(67.19%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>Mucinous </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>14 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>11(81.25%) </plain></SENT>
</text></td><td align="right" valign="middle" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>3(18.75%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>Endometrioid </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>1(75%) </plain></SENT>
</text></td><td align="right" valign="middle" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>3(25%) </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" colspan="2" rowspan="1"><text><SENT sid="99" pm="."><plain>Serous versus non-serous </plain></SENT>
</text></td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>&gt;0.005 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title><text><SENT sid="101" pm="."><plain>Immunohistochemical analysis of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in ovarian cancer </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was predominantly localized in the (A) plasma membrane, (B, C, D, E) cytoplasm. </plain></SENT>
<SENT sid="103" pm="."><plain>The expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in different types of ovarian cancer samples. </plain></SENT>
<SENT sid="104" pm="."><plain>(A). serous papillary adenocarcinoma (stage I); (B). serous papillary adenocarcinoma (stage IIIA); (C). serous papillary adenocarcinoma (stage IIIC); (D). mucinous adenocarcinoma mucinous adenocarcinoma (stage IA); (E). mucinous adenocarcinoma mucinous adenocarcinoma (stage IB) ; (F). mucinous adenocarcinoma mucinous adenocarcinoma (stage III); (G). endometrioid adenocarcinoma(stage I); (H). endometrioid adenocarcinoma(stage III); (I). normal ovarian tissue. </plain></SENT>
<SENT sid="105" pm="."><plain>Original magnification, 200X. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-06-12174-g001"/></fig></SecTag></sec><sec id="s2_2"><title><text><SENT sid="106" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in ovarian cancer cell lines </plain></SENT>
</text></title><p><text><SENT sid="107" pm="."><plain>The expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was investigated in 7 cell lines at the mRNA level by real-time quantitative PCR (qPCR) to select suitable cell lines for functional assays. </plain></SENT>
<SENT sid="108" pm="."><plain>Of these, <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression was higher in the SKOV3, CaOV-3, and Es-2 cell lines, than in the A2780 cell line (Fig. 2A). </plain></SENT>
<SENT sid="109" pm="."><plain>Therefore, A2780 cell line was selected for exogenous expression; SKOV3 cell was selected for down -regulation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> to determine the <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> functions. </plain></SENT>
<SENT sid="110" pm="."><plain>The mRNA and protein level of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was decreased in LV3-shMARCH7-1 or LV3-shMARCH7-2 infected SKOV3 cells compared with LV3-NC SKOV3 cells (Fig. 2B and 2C). </plain></SENT>
</text></p></sec><sec id="s2_3"><title><text><SENT sid="111" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> regulates cellular proliferation </plain></SENT>
</text></title><p><text><SENT sid="112" pm="."><plain>Our data showed that downregulation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> using LV3-shMARCH7-1 and LV3-shMARCH7-2 could inhibit cell proliferation in ovarian cancer SKOV3 cell (P &lt; 0.05; Fig. 2D, 2E and 2F). </plain></SENT>
<SENT sid="113" pm="."><plain>The efficiency of colony formation had decreased in LV3-shMARCH7-1 or LV3-shMARCH7-2 infected SKOV3 cells (P&lt;0.05) (Fig. 2G and 2H). </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>On the other hand, we investigated the overexpression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in A2780 cell by exposing them to LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>. </plain></SENT>
<SENT sid="115" pm="."><plain>Our data showed that overexpression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in A2780 cells resulted in an increase in cell proliferation compared to LV-5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot>-exposed cells (P &lt; 0.05; Fig. 2I, 2J and 2K). </plain></SENT>
<SENT sid="116" pm="."><plain>This was consistent with the exogenous expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> that increased the colony forming capacity in contrast with LV-5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot> infected cells (P &lt; 0.05) (Fig. 2L and 2M). </plain></SENT>
<SENT sid="117" pm="."><plain>However, <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> knockdown did not induce cell apoptosis (data not presented). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title><text><SENT sid="118" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> regulated the proliferation of ovarian cancer SKOV3 and A2780 cells </plain></SENT>
</text></title><p><text><SENT sid="119" pm="."><plain>(A) The relative expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> mRNA in ovarian cancer cell lines. </plain></SENT>
<SENT sid="120" pm="."><plain>(B, C) <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> mRNA and protein level were down-regulated by infected with LV3-shMARCH7-1 or LV3-shMARCH7-2. </plain></SENT>
<SENT sid="121" pm="."><plain>(D, E) Ovarian cancer SKOV3 cells were infected with LV3-NC, LV3-shMARCH7-1 and LV3-shMARCH7-2. </plain></SENT>
<SENT sid="122" pm="."><plain>Cell proliferation was assessed by EdU. </plain></SENT>
<SENT sid="123" pm="."><plain>The proliferation rate of LV3-shMARCH7-1 and LV3-shMARCH7-2 cells was lower than that of LV3-NC cells. </plain></SENT>
<SENT sid="124" pm="."><plain>Original magnification, 200X. </plain></SENT>
<SENT sid="125" pm="."><plain>(F) Cell proliferation was determined by <z:uniprot sup="inside" fb="88" ids="P41520,Q9TS44,Q9PU41,P68125,P06307,P80344,P68126,P23362,P0C229,P09240,O57312,P01356,P01355,Q9PU29,P80345,Q8JHB9">CCK</z:uniprot>-8 assay. </plain></SENT>
<SENT sid="126" pm="."><plain>(G, H) Colony formation assay. </plain></SENT>
<SENT sid="127" pm="."><plain>Skov3 cells infected with Lv3-shMarch7-1 or Lv3-shMarch7-2 were cultured by seeding 1,000 cells in 6-well plates and enumerating the number of colonies formed in 2 weeks. </plain></SENT>
<SENT sid="128" pm="."><plain>The number of colony formation of LV3-shMARCH7-1 or LV3-shMARCH7-2 was lower as compared with LV3-NC. </plain></SENT>
<SENT sid="129" pm="."><plain>(I, J) Ovarian cancer A2780 cells were infected with LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot> or LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>. </plain></SENT>
<SENT sid="130" pm="."><plain>Then cell proliferation was determined by EdU. </plain></SENT>
<SENT sid="131" pm="."><plain>Original magnification, 200X. </plain></SENT>
<SENT sid="132" pm="."><plain>The proliferation rate of LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> cells was increased compared with LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot> cells. </plain></SENT>
<SENT sid="133" pm="."><plain>(K) Cell proliferation was determined by <z:uniprot sup="inside" fb="88" ids="P41520,Q9TS44,Q9PU41,P68125,P06307,P80344,P68126,P23362,P0C229,P09240,O57312,P01356,P01355,Q9PU29,P80345,Q8JHB9">CCK</z:uniprot>-8 assay. </plain></SENT>
<SENT sid="134" pm="."><plain>(L, M) Colony formation assay. </plain></SENT>
<SENT sid="135" pm="."><plain>A2780 cells infected with LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> were cultured by seeding 1000 cells in 6-well plates and counting the number of colonies formed in 2 weeks. </plain></SENT>
<SENT sid="136" pm="."><plain>The number of colony formation of LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was higher as compared with LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot>. </plain></SENT>
<SENT sid="137" pm="."><plain>Error bars represent standard error. * p &lt; 0.05, and **p &lt; 0.001. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-06-12174-g002"/></fig></SecTag></sec><sec id="s2_4"><title><text><SENT sid="138" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression modulates cellular migration, invasion in vitro and induces F-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> remodeling </plain></SENT>
</text></title><p><text><SENT sid="139" pm="."><plain>Migration of cells and invasion of tissues are important prerequisites for tumor progression and metastasis. </plain></SENT>
<SENT sid="140" pm="."><plain>To investigate whether <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> modulated cellular migration and invasion, we performed a matrigel invasion assay and wound healing test. </plain></SENT>
<SENT sid="141" pm="."><plain>Wound-healing and trans-well invasion assays both demonstrated that the migration and invasion capabilities of SKOV3 cell were significantly suppressed when <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was silenced by LV3-shMARCH7-1 or LV3-shMARCH7-2 (p &lt; 0.05) (Fig. 3A, 3B, 3C, and 3D). </plain></SENT>
<SENT sid="142" pm="."><plain>At the same time, we found that the migration and invasion capabilities of A2780 cells were significantly promoted when <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was overexpressed with a lentiviral vector expressing <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> (LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>) (P &lt; 0.05) (Fig. 3E, 3F, 3G, and 3H). </plain></SENT>
<SENT sid="143" pm="."><plain>Cellular migration and invasion is dependent on localized <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> polymerization at the leading edge of the cells. </plain></SENT>
<SENT sid="144" pm="."><plain>Polymerization of globular <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> leads to the formation of long fibrous molecules, F-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot>. </plain></SENT>
<SENT sid="145" pm="."><plain>In eukaryotic cells, cell migration requires the formation of cell membrane extensions containing <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> filaments [5]. </plain></SENT>
<SENT sid="146" pm="."><plain>Because overexpression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in A2780 cells caused a marked increase in the cellular migration and invasion, and silencing of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in SK0V3 cells caused a marked decreased in the cellular migration and invasion, we analyzed the alterations in the pattern of the F-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> in SKOV3 and A2780 by silencing or ectopic expression <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> respectively. </plain></SENT>
<SENT sid="147" pm="."><plain>In LV3-NC infected SKOV3 cells, F-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> staining was predominantly localized in the cellular outgrowth and projections. </plain></SENT>
<SENT sid="148" pm="."><plain>In contrast, in LV3-shMARCH7-1 or LV3-shMARCH7-2 infected SKOV3 cells, F-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> staining was homogenous throughout the cytoplasm, and the formation of membrane ruffles and lamellipodia was prevented (Fig. 3I). </plain></SENT>
<SENT sid="149" pm="."><plain>LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot>-infected A2780 cells displayed some small lamellipodia and ruffles. </plain></SENT>
<SENT sid="150" pm="."><plain>In contrast, LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> infected A2780 cells showed F-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> reorganization in membrane ruffles and lamellipodia (Fig. 3J). </plain></SENT>
<SENT sid="151" pm="."><plain>These results suggest that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> can modulate cellular dynamics by reorganization of the <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> cytoskeleton. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="152" pm="."><plain>(A, B) Ovarian cancer SKOV3 cells migration ability was detected by the wound healing assay. </plain></SENT>
<SENT sid="153" pm="."><plain>The migration of LV3-shMARCH7-1 and LV3-shMARCH7-2 infected SKOV3 cells was lower as compared with LV3-NC infected cells. </plain></SENT>
<SENT sid="154" pm="."><plain>(C, D) Ovarian cancer SKOV3 cells invasion ability was detected by Matrigel invasion assays. </plain></SENT>
<SENT sid="155" pm="."><plain>The invasion ability of LV3-shMARCH7-1 and LV3-shMARCH7-2 infected SKOV3 cells was decreased compared with LV3-NC infected cells. </plain></SENT>
<SENT sid="156" pm="."><plain>(E, F) Ovarian cancer A2780 cells migration ability was detected by wound healing assay. </plain></SENT>
<SENT sid="157" pm="."><plain>The migration ability of LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> infected A2780 cells was increased compared with LV3-NC infected cells. </plain></SENT>
<SENT sid="158" pm="."><plain>(G, H) Ovarian cancer A2780 cells invasion ability was detected by Matrigel invasion assays. </plain></SENT>
<SENT sid="159" pm="."><plain>The invasion ability of LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> infected A2780 cells was increased compared with LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot> infected cells. </plain></SENT>
<SENT sid="160" pm="."><plain>(I, J). </plain></SENT>
<SENT sid="161" pm="."><plain>F-<z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> staining. </plain></SENT>
<SENT sid="162" pm="."><plain>Original magnification, 400X. </plain></SENT>
<SENT sid="163" pm="."><plain>Error bars represent standard error. * p &lt; 0.05, and **p &lt; 0.001. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-06-12174-g003"/></fig></SecTag></sec><sec id="s2_5"><title><text><SENT sid="164" pm="."><plain>TGF-β1, <z:uniprot sup="inside" fb="0" ids="P59684,Q1G1A2,Q06599,P59693,Q2MH05,Q19LH4,Q75N23,P51742,P13296,P51435,P51743,Q1WM27,Q8WNR1,P19101,P29553,P01375,P59694,O77764,P79337,P48094,O35734,P06804,Q8HZD9,P59695,O77510,P33620,P36939,P23563,P04924,P16599,Q8MKG8,P23383,Q8JFG3,P79374,Q539C2,Q9BEA1">TNF-α</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P09428,Q2MH07,Q28292,P79162,Q9WVG1,P46648,P51745,Q8WNR2,Q6R2X3,P41687,Q28386,P01584,Q865X8,P79182,P48090,P51493,P10749,A4UYK8,Q6PUD2,P26889,Q2HZH0,P14628,Q63264,P21621,Q9XS77">IL-1β</z:uniprot> regulate the expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> </plain></SENT>
</text></title><p><text><SENT sid="165" pm="."><plain>Transforming <z:uniprot sup="inside" fb="0" ids="Q8V307,Q776B5,P08072,Q6RZT5,P08441">growth factor</z:uniprot> (TGF)-β1, <z:uniprot sup="inside" fb="0" ids="P59684,Q1G1A2,Q06599,P59693,Q2MH05,Q19LH4,Q75N23,P51742,P13296,P51435,P51743,Q1WM27,Q8WNR1,P19101,P29553,P01375,P59694,O77764,P79337,P48094,O35734,P06804,Q8HZD9,P59695,O77510,P33620,P36939,P23563,P04924,P16599,Q8MKG8,P23383,Q8JFG3,P79374,Q539C2,Q9BEA1">tumor necrosis factor</z:uniprot>-alpha (<z:uniprot sup="inside" fb="0" ids="P59684,Q1G1A2,Q06599,P59693,Q2MH05,Q19LH4,Q75N23,P51742,P13296,P51435,P51743,Q1WM27,Q8WNR1,P19101,P29553,P01375,P59694,O77764,P79337,P48094,O35734,P06804,Q8HZD9,P59695,O77510,P33620,P36939,P23563,P04924,P16599,Q8MKG8,P23383,Q8JFG3,P79374,Q539C2,Q9BEA1">TNF-α</z:uniprot>) and <z:uniprot sup="inside" fb="0" ids="P09428,Q2MH07,Q28292,P79162,Q9WVG1,P46648,P51745,Q8WNR2,Q6R2X3,P41687,Q28386,P01584,Q865X8,P79182,P48090,P51493,P10749,A4UYK8,Q9YGD3,Q6PUD2,P26889,Q2HZH0,P14628,Q63264,P21621,Q9XS77">Interleukin-1β</z:uniprot> are expressed in ovarian cancer, which can promote ovarian tumorigenesis through an inflammatory response [6-8]. </plain></SENT>
<SENT sid="166" pm="."><plain>Hence, we explored the possibility of whether TGF-β1, <z:uniprot sup="inside" fb="0" ids="P59684,Q1G1A2,Q06599,P59693,Q2MH05,Q19LH4,Q75N23,P51742,P13296,P51435,P51743,Q1WM27,Q8WNR1,P19101,P29553,P01375,P59694,O77764,P79337,P48094,O35734,P06804,Q8HZD9,P59695,O77510,P33620,P36939,P23563,P04924,P16599,Q8MKG8,P23383,Q8JFG3,P79374,Q539C2,Q9BEA1">TNF-α</z:uniprot>, and <z:uniprot sup="inside" fb="0" ids="P09428,Q2MH07,Q28292,P79162,Q9WVG1,P46648,P51745,Q8WNR2,Q6R2X3,P41687,Q28386,P01584,Q865X8,P79182,P48090,P51493,P10749,A4UYK8,Q9YGD3,Q6PUD2,P26889,Q2HZH0,P14628,Q63264,P21621,Q9XS77">interleukin-1β</z:uniprot> can mediate <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in SKOV3 cells. </plain></SENT>
<SENT sid="167" pm="."><plain>Ovarian cancer SKOV3 cells were treated with TGF-β1 (0, 10, 20, 30 ng/mL), <z:uniprot sup="inside" fb="0" ids="P59684,Q1G1A2,Q06599,P59693,Q2MH05,Q19LH4,Q75N23,P51742,P13296,P51435,P51743,Q1WM27,Q8WNR1,P19101,P29553,P01375,P59694,O77764,P79337,P48094,O35734,P06804,Q8HZD9,P59695,O77510,P33620,P36939,P23563,P04924,P16599,Q8MKG8,P23383,Q8JFG3,P79374,Q539C2,Q9BEA1">TNF-α</z:uniprot> (0, 10, 20, 30 ng/mL) or <z:uniprot sup="inside" fb="0" ids="P09428,Q2MH07,Q28292,P79162,Q9WVG1,P46648,P51745,Q8WNR2,Q6R2X3,P41687,Q28386,P01584,Q865X8,P79182,P48090,P51493,P10749,A4UYK8,Q9YGD3,Q6PUD2,P26889,Q2HZH0,P14628,Q63264,P21621,Q9XS77">interleukin-1β</z:uniprot> (0, 10, 20, 30 ng/mL) for 48 hours. </plain></SENT>
<SENT sid="168" pm="."><plain>TGF-β1 increased the mRNA and protein level of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> at 10 ng/mL than that untreated. </plain></SENT>
<SENT sid="169" pm="."><plain>However, the mRNA and protein levels were lower in cells treated with TGF-β1 20 ng/mL or 30 ng/mL. </plain></SENT>
<SENT sid="170" pm="."><plain>The changes in the mRNA and protein levels of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in response to <z:uniprot sup="inside" fb="0" ids="P59684,Q1G1A2,Q06599,P59693,Q2MH05,Q19LH4,Q75N23,P51742,P13296,P51435,P51743,Q1WM27,Q8WNR1,P19101,P29553,P01375,P59694,O77764,P79337,P48094,O35734,P06804,Q8HZD9,P59695,O77510,P33620,P36939,P23563,P04924,P16599,Q8MKG8,P23383,Q8JFG3,P79374,Q539C2,Q9BEA1">TNF-α</z:uniprot> or <z:uniprot sup="inside" fb="0" ids="P09428,Q2MH07,Q28292,P79162,Q9WVG1,P46648,P51745,Q8WNR2,Q6R2X3,P41687,Q28386,P01584,Q865X8,P79182,P48090,P51493,P10749,A4UYK8,Q9YGD3,Q6PUD2,P26889,Q2HZH0,P14628,Q63264,P21621,Q9XS77">interleukin-1β</z:uniprot> was similar to that with TGF-β1 treatment at (0, 10, 20, 30 ng/mL) (Fig. 4A and Fig. </plain></SENT>
<SENT sid="171" pm="."><plain><z:uniprot sup="inside" fb="3" ids="P28878,P02350">S1A</z:uniprot>-C). </plain></SENT>
<SENT sid="172" pm="."><plain>Our results indicated that TGF-β1, <z:uniprot sup="inside" fb="0" ids="P59684,Q1G1A2,Q06599,P59693,Q2MH05,Q19LH4,Q75N23,P51742,P13296,P51435,P51743,Q1WM27,Q8WNR1,P19101,P29553,P01375,P59694,O77764,P79337,P48094,O35734,P06804,Q8HZD9,P59695,O77510,P33620,P36939,P23563,P04924,P16599,Q8MKG8,P23383,Q8JFG3,P79374,Q539C2,Q9BEA1">TNF-α</z:uniprot>, and <z:uniprot sup="inside" fb="0" ids="P09428,Q2MH07,Q28292,P79162,Q9WVG1,P46648,P51745,Q8WNR2,Q6R2X3,P41687,Q28386,P01584,Q865X8,P79182,P48090,P51493,P10749,A4UYK8,Q9YGD3,Q6PUD2,P26889,Q2HZH0,P14628,Q63264,P21621,Q9XS77">interleukin-1β</z:uniprot> regulated <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression to promote tumor metastasis of ovarian cancer. </plain></SENT>
</text></p></sec><sec id="s2_6"><title><text><SENT sid="173" pm="."><plain>Ectopic expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> increased NF-κB and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> signal pathway <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> reporter activity </plain></SENT>
</text></title><p><text><SENT sid="174" pm="."><plain>Our data indicated that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> might have been involved in cellular proliferation, migration, and invasion. </plain></SENT>
<SENT sid="175" pm="."><plain>Hence, we believe that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> might mediate some signal pathway, which is associated with ovarian cancer. </plain></SENT>
<SENT sid="176" pm="."><plain>We detected NF-κB, <z:uniprot sup="inside" fb="141" ids="P46530">Notch</z:uniprot>, <z:uniprot sup="inside" fb="117" ids="Q29537,O09185,Q8SPZ3,P79892,P04637,P56423,P61260,P56424,P02340,Q9TUB2,P10361,Q9TTA1">P53</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> signal pathway <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> reporter activity by ectopic expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer A2780 cells infected with LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>. </plain></SENT>
<SENT sid="177" pm="."><plain>We found that ectopic expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer A2780 cells significantly increased the NF-κB and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathway <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> reporter activities (P &lt; 0.01) (Fig. </plain></SENT>
<SENT sid="178" pm="."><plain>S1D). </plain></SENT>
<SENT sid="179" pm="."><plain>Hence, we hypothesize that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> may regulate NF-κB and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> signal pathway. </plain></SENT>
</text></p></sec><sec id="s2_7"><title><text><SENT sid="180" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> mediates NF-kB pathway in ovarian cancer SKOV3 and A2780 cells </plain></SENT>
</text></title><p><text><SENT sid="181" pm="."><plain>The silencing of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in SKOV3 cells caused a marked decrease in NF-κB <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity (P&lt;0.05), that was consistent with the above results (Fig. </plain></SENT>
<SENT sid="182" pm="."><plain>S1E). </plain></SENT>
<SENT sid="183" pm="."><plain><z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> and <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> protein levels were decreased in SKOV3 cells when <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was silenced (Fig. 4B(I)). </plain></SENT>
<SENT sid="184" pm="."><plain>Ectopic <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> gene expression in A2780 cells increased the protein level <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> and <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> (Fig. 4B(II)). </plain></SENT>
<SENT sid="185" pm="."><plain>We tested whether <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> regulated nuclear localization of individual NF-κB in ovarian cancer cells such as SKOV3 and A2780. </plain></SENT>
<SENT sid="186" pm="."><plain>The decrease in nuclear translocation of NF kB <z:uniprot sup="inside" fb="2" ids="E1QC64,P0CJ81,P41823,P21521,P48018,P47191,P21579,P46096,P21707,Q9H4A3">p65</z:uniprot> and <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> after transfection to SKOV3 cells were observed with LV3-shMARCH7-1 or LV3-shMARCH7-2 as compared to that of LV3-NC (P&lt;0.05) (Fig. 5A and 5B). </plain></SENT>
<SENT sid="187" pm="."><plain>Increase in nuclear translocation of NF kB <z:uniprot sup="inside" fb="2" ids="E1QC64,P0CJ81,P41823,P21521,P48018,P47191,P21579,P46096,P21707,Q9H4A3">p65</z:uniprot> and <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> were observed after infection of A2780 cells with LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> as compared with that of LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot> (P &lt; 0.05) (Fig. 5A and 5B). </plain></SENT>
</text></p><p><text><SENT sid="188" pm="."><plain>Next, we determined whether NF-κB pathway could regulate <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>. </plain></SENT>
<SENT sid="189" pm="."><plain>Inhibition of NF-κB signaling in SKOV3 cells by PTDC caused a reduction in the levels of mRNA and protein of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>, with the reduction corresponding to an increase in the PTDC concentration (0, 10, 30 50 uM) (Fig. 4A and S1F). </plain></SENT>
<SENT sid="190" pm="."><plain>The mRNA and protein level of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in SKOV3 cells were lowered after transfection with <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> or <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> (Fig. 4A and S1G). </plain></SENT>
<SENT sid="191" pm="."><plain>Our data suggested <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> interact with NF kB pathway. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p><text><SENT sid="192" pm="."><plain>(A) The expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> protein level in SKOV3 cells was regulated by TGF-β1, <z:uniprot sup="inside" fb="0" ids="P59684,Q1G1A2,Q06599,P59693,Q2MH05,Q19LH4,Q75N23,P51742,P13296,P51435,P51743,Q1WM27,Q8WNR1,P19101,P29553,P01375,P59694,O77764,P79337,P48094,O35734,P06804,Q8HZD9,P59695,O77510,P33620,P36939,P23563,P04924,P16599,Q8MKG8,P23383,Q8JFG3,P79374,Q539C2,Q9BEA1">TNF-α</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="P09428,Q2MH07,Q28292,P79162,Q9WVG1,P46648,P51745,Q8WNR2,Q6R2X3,P41687,Q28386,P01584,Q865X8,P79182,P48090,P51493,P10749,A4UYK8,Q6PUD2,P26889,Q2HZH0,P14628,Q63264,P21621,Q9XS77">IL-1β</z:uniprot>, PTDC, NFkB <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> and NFkB <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot>.(B) The protein expression level in SKOV3 and A2780 cells of NFkB <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot>, NFkB <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> was detected by western blot. </plain></SENT>
<SENT sid="193" pm="."><plain>(C-I) A putative binding site targeted by miR-101 was predicted to be located in 3′UTR of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> mRNA. </plain></SENT>
<SENT sid="194" pm="."><plain>(C-II)SKOV3 cells were co-transfected with miR-101 mimics or control RNA [negative control (NC)] with <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> reporter plasmids containing either wild type (pMIR-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>-3UTR) or mutant 3′UTR (pMIR-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>-3UTRm) of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> gene. </plain></SENT>
<SENT sid="195" pm="."><plain><z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">Luciferase</z:uniprot> expression was measured. </plain></SENT>
<SENT sid="196" pm="."><plain>The fold changes of relative <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity in miR-101 mimics with indicated plasmids transfected cells were normalized to NC with corresponding indicated plasmids transtected cells, respectively. </plain></SENT>
<SENT sid="197" pm="."><plain>(C-III)The expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> protein levels was detected by western blot. </plain></SENT>
<SENT sid="198" pm="."><plain>(D) Ovarian cancer SKOV3 cells migration ability was detected by the wound healing assay. </plain></SENT>
<SENT sid="199" pm="."><plain>(E) Ovarian cancer SKOV3 cells invasion ability was detected by Matrigel invasion assays. </plain></SENT>
<SENT sid="200" pm="."><plain>(F) Cell proliferation was determined by <z:uniprot sup="inside" fb="88" ids="P41520,Q9TS44,Q9PU41,P68125,P06307,P80344,P68126,P23362,P0C229,P09240,O57312,P01356,P01355,Q9PU29,P80345,Q8JHB9">CCK</z:uniprot>-8 assay. * p&lt;0.05, and **p&lt;0.001. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-06-12174-g004"/></fig></SecTag></sec><sec id="s2_8"><title><text><SENT sid="201" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> regulates Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathway in ovarian cancer SKOV3 and A2780 cell </plain></SENT>
</text></title><p><text><SENT sid="202" pm="."><plain>Consistent with the above results, the level of <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> protein expressed in LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>-infected A2780 cells were significantly higher than that of LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot>-infected A2780 cells (Fig. 4B(I)). </plain></SENT>
<SENT sid="203" pm="."><plain>In contrast, LV3-shMARCH7-1 or LV3-shMARCH7-2 infected cells decreased TOP-flash <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity, and the expression of <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> protein than that of LV3-NC-infected SKOV3 cells (Fig.4B(II) and S1H). </plain></SENT>
</text></p><p><text><SENT sid="204" pm="."><plain>Non-phosphorylated <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> has been identified as the transcriptionally active form of <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> in the nucleus. </plain></SENT>
<SENT sid="205" pm="."><plain>Therefore, we determined if <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> promoted <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> translocation to the nuclei of SKOV3 and A2780 cells. </plain></SENT>
<SENT sid="206" pm="."><plain>A2780 cells exposed to LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> resulted in significantly higher levels of <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> proteins in both the cytoplasm and the nuclei, relative to LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot>-infected A2780 cells (P &lt; 0.05) (Fig. 5A and 5B). </plain></SENT>
<SENT sid="207" pm="."><plain>Conversely, LV3-shMARCH7-1 or LV3-shMARCH7-2 infected SKOV3 cells showed a decrease in both, the cytoplasmic and nuclear expression levels of <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> relative to LV3-NC-infected SKOV3 cells (P &lt; 0.05) (Fig. 5A and 5B). </plain></SENT>
<SENT sid="208" pm="."><plain>These findings suggested that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> activation of <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> results in nuclear translocation and accumulation, thereby enabling it to regulate expression of genes associated with tumorigenesis. </plain></SENT>
</text></p><p><text><SENT sid="209" pm="."><plain>C-<z:uniprot sup="inside" fb="92" ids="P06171,P52160,P49709,P06646">myc</z:uniprot>, sp5, <z:uniprot sup="inside" fb="0" ids="P27782">lef1</z:uniprot> play key roles in the Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> signaling pathway [9-11]. </plain></SENT>
<SENT sid="210" pm="."><plain>Therefore, we determined the expression of their respective mRNAs by qPCR by silencing <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in SKOV3 cells, and ectopic expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in A2780 cells. </plain></SENT>
<SENT sid="211" pm="."><plain>The results showed that mRNA levels of <z:uniprot sup="inside" fb="0" ids="Q17103">c-myc</z:uniprot>, sp5, <z:uniprot sup="inside" fb="0" ids="P27782">lef1</z:uniprot> were significantly higher in LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>-infected A2780 cells (P &lt; 0.05) (Fig. </plain></SENT>
<SENT sid="212" pm="."><plain>S1I); whereas, they were significantly lower in LV3-shMARCH7-1 or LV3-shMARCH7-2 infected SKOV3 cells, relative to LV3-NC infected SKOV3 cells (P &lt; 0.05) (Fig. </plain></SENT>
<SENT sid="213" pm="."><plain>S1J). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><p><text><SENT sid="214" pm="."><plain>(A) The expression of NFkB <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot>, NFkB <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot>, and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> was detected by immunofluorescence staining in ovarian cancer SKOV3 cells (LV3-shMARCH7-1 or LV3-shMARCH7-2 infected) and A2780 cells (LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> infected). </plain></SENT>
<SENT sid="215" pm="."><plain>(B). </plain></SENT>
<SENT sid="216" pm="."><plain>The nuclear translocation of NFkB <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot>, NFkB <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot>, and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> was decreased in LV3-shMARCH7-1 or LV3-shMARCH7-2 infected ovarian cancer SKOV3 cells as compared with LV3-NC infected cells. </plain></SENT>
<SENT sid="217" pm="."><plain>The nuclear translocation of NFkB <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot>, NFkB <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot>, and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> was increased in LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> infected ovarian cancer A2780 cells compared with LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot> infected cells. </plain></SENT>
<SENT sid="218" pm="."><plain>Original magnification ×200. </plain></SENT>
<SENT sid="219" pm="."><plain>Data are expressed as Mean ± SD from three independent experiments. * p &lt; 0.05, and **p &lt; 0.001. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-06-12174-g005"/></fig></SecTag></sec><sec id="s2_9"><title><text><SENT sid="220" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> regulates the protein levels of <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot> in ovarian cancer SKOV3 cells </plain></SENT>
</text></title><p><text><SENT sid="221" pm="."><plain>Intercellular adhesion correlates with the presence of <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot> and catenin complexes. </plain></SENT>
<SENT sid="222" pm="."><plain>It regulates <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> transport to the cell nucleus to activate the transcription of many genes [12, 13]. </plain></SENT>
<SENT sid="223" pm="."><plain>Therefore, we explored whether <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> regulated the expression level of <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot> protein. </plain></SENT>
<SENT sid="224" pm="."><plain>The results showed that protein levels of <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot> were significantly decreased in LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>-infected A2780 cells (Fig. 4B(I)); whereas, they were significantly increased in LV3-shMARCH7-1 or LV3-shMARCH7-2 infected SKOV3 cells, relative to LV3-NC infected SKOV3 cells (Fig. 4B(II)) </plain></SENT>
</text></p></sec><sec id="s2_10"><title><text><SENT sid="225" pm="."><plain>MiR-101 regulates <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in ovarian cancers </plain></SENT>
</text></title><p><text><SENT sid="226" pm="."><plain>Bioinformatics analyses using multiple algorithms showed that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> is a predictive target of miR-101(http://www.targetscan.org/). </plain></SENT>
<SENT sid="227" pm="."><plain>Thus, we experimentally verified whether miR-101 modulated <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in SKOV3 cells. </plain></SENT>
<SENT sid="228" pm="."><plain>We predicted that miR-101-specific binding site was located within the 3′UTR of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> mRNA (Fig. 4C(I)). </plain></SENT>
<SENT sid="229" pm="."><plain>We constructed a vector to investigate if miR-101 could directly target <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> 3′UTR. </plain></SENT>
<SENT sid="230" pm="."><plain>We found that miR-101 markedly inhibited <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity when <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> 3′UTR was inserted downstream of <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> cDNA in our reporter vector (pMIR-MARCH73UTR). </plain></SENT>
<SENT sid="231" pm="."><plain>In contrast, no significant suppressive effect on <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity was observed in cells transfected with a control vector with mutant <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> 3′UTR (<z:uniprot sup="inside" fb="119" ids="Q93105,Q5T0T0,P13087,Q9HAP2,Q8WY64,Q8BM54,D3ZDI6">MIR</z:uniprot>- MARCH73UTRm), when miR-101 expression was elevated (Fig. 4C(II)). </plain></SENT>
<SENT sid="232" pm="."><plain>We also found that miR-101 mimics could downregulate the mRNA and protein level of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> (Fig. 4C(III) and S1K). </plain></SENT>
</text></p><p><text><SENT sid="233" pm="."><plain>We also found that expression of miR-101 inhibited proliferation, migration and invasion of SKOV3 cells. </plain></SENT>
<SENT sid="234" pm="."><plain>The phenotypes can be partially restored expression of a miR-101 resistant <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> (Fig. 4D, 4E and 4F). </plain></SENT>
<SENT sid="235" pm="."><plain>These data indicate that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> is a direct target of miR-101. </plain></SENT>
</text></p></sec><sec id="s2_11"><title><text><SENT sid="236" pm="."><plain>Downregulation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> abolished tumorigenicity of ovarian cancer SKOV3 cell </plain></SENT>
</text></title><p><text><SENT sid="237" pm="."><plain>The role of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in tumor formation of ovarian cancer SKOV3 cells was investigated in an animal model. </plain></SENT>
<SENT sid="238" pm="."><plain>LV3-shMARCH7-1 and LV3-NC infected SKOV3 cells formed tumors in all nude mice. </plain></SENT>
<SENT sid="239" pm="."><plain>The average weight of tumors was significantly lower in LV3-shMARCH7-1 infected group than that in LV3-NC infected group (P &lt; 0.01) (Fig. 6A and 6B). </plain></SENT>
<SENT sid="240" pm="."><plain>The average volume of tumors in LV3-shMARCH7-1 infected group was significantly lower than that of the LV3-NC infected group (P &lt; 0.01; Fig. 6A and 6B). </plain></SENT>
<SENT sid="241" pm="."><plain>IHC revealed that the expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>, <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot>, <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> in tumors from LV3-shMARCH7-1 infected group was lower than that in the LV3-NC infected group (P &lt; 0.05) (Fig. 6C and S2A). </plain></SENT>
<SENT sid="242" pm="."><plain>These data show that silencing <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> blocks tumor formation in vivo. <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> can regulate the expression of <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot>, <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> in vivo. </plain></SENT>
<SENT sid="243" pm="."><plain>We also found that A2780 cells infected LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> increased the average weight of tumors and the average volume of tumors than that of the LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot> infected group (P &lt; 0.01; Fig. 6D and 6E). </plain></SENT>
<SENT sid="244" pm="."><plain>IHC revealed that the expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>, <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot>, <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> in tumors from LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> infected group was increased than that in the LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot> infected group (P &lt; 0.05) (Fig. 6F and S2B). </plain></SENT>
<SENT sid="245" pm="."><plain>These data show that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> promoted tumor formation in vivo. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title><text><SENT sid="246" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> regulated tumorigenesis in nude mice model </plain></SENT>
</text></title><p><text><SENT sid="247" pm="."><plain>(A, B) Mean tumor volume and weight on day 21 after tumor cell injection. </plain></SENT>
<SENT sid="248" pm="."><plain>LV3-shMARCH7-1 or LV3-NC infected SKOV3 cells were implanted s.c. into the left armpit. </plain></SENT>
<SENT sid="249" pm="."><plain>(C). </plain></SENT>
<SENT sid="250" pm="."><plain>Immunohistochemical analysis of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>, NFkB <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot>, NFkB <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot>, and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> expression were performed on tumor xenografts. </plain></SENT>
<SENT sid="251" pm="."><plain>Representative images are shown (original magnification ×200). </plain></SENT>
<SENT sid="252" pm="."><plain>(D, E) Mean tumor volume and weight on day 21 after tumor cell injection. </plain></SENT>
<SENT sid="253" pm="."><plain>LV5-<z:uniprot sup="inside" fb="2" ids="P42212">GFP</z:uniprot> or LV5-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> infected A2780 cells were implanted s.c. into the left armpit. </plain></SENT>
<SENT sid="254" pm="."><plain>(F) Immunohistochemical analysis of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>, NFkB <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot>, NFkB <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot>, and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> expression were performed on tumor xenografts. </plain></SENT>
<SENT sid="255" pm="."><plain>Representative images are shown (original magnification ×200). * p &lt; 0.05, and **p &lt; 0.001. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-06-12174-g006"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s3"><title><text><SENT sid="256" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="257" pm="."><plain>In this study, we noted that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression was higher in ovarian cancer tissues, compared to normal ovarian tissues. </plain></SENT>
<SENT sid="258" pm="."><plain>We also observed that overexpression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer correlated with tumor stage and histological grades. </plain></SENT>
<SENT sid="259" pm="."><plain>Our results showed that up-regulation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in ovarian cancer increased cellular migration, invasion, and cell proliferation in vitro with remarkable changes in the cytoskeleton. </plain></SENT>
<SENT sid="260" pm="."><plain>These results suggest that elevated levels of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> aids in the progress of ovarian cancer, and promotes an aggressive behavior, indicating that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> may function as a novel tumor marker and a potential therapeutic target for ovarian cancer. </plain></SENT>
<SENT sid="261" pm="."><plain>Our data also demonstrates that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> can regulate nuclear factor kB (NF-kB) and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathway, and that <z:uniprot sup="inside" fb="119" ids="Q93105,Q5T0T0,P13087,Q9HAP2,Q8WY64,Q8BM54,D3ZDI6">MIR</z:uniprot>-101 controls <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> by targeting MATCH7 3′UTR region. </plain></SENT>
</text></p><p><text><SENT sid="262" pm="."><plain>In addition to the investigation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer, we explored the role of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer. </plain></SENT>
<SENT sid="263" pm="."><plain>We found that inhibiting <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in ovarian cancer SKOV3 cells suppressed cancer cell activities, whereas overexpression <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer A2780 cells increased cancer cell activities such as growth, migration, and invasion. </plain></SENT>
<SENT sid="264" pm="."><plain>In a living cell, the <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> cytoskeleton continuously undergoes remodeling at a constant rate. </plain></SENT>
<SENT sid="265" pm="."><plain>This dynamics are based on predictive controlled equilibrium, and a dynamic balance of <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> filaments. </plain></SENT>
<SENT sid="266" pm="."><plain>This regulation is crucial for cell motility, and cancer cell invasion [14-16]. </plain></SENT>
<SENT sid="267" pm="."><plain>In our study, we found that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> regulated localization in the cellular, membrane lamellipodia, and ruffles. </plain></SENT>
<SENT sid="268" pm="."><plain>These results indicate that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> is a novel regulator of ovarian cancer progression through its effect on <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> cytoskeletal alterations. </plain></SENT>
<SENT sid="269" pm="."><plain>Most importantly, downregulation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer cells could abolish their tumorigenecity. </plain></SENT>
</text></p><p><text><SENT sid="270" pm="."><plain>Until now, there is no study implicating <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in the pathogenesis of cancer, the mechanisms of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in cancer development and progression are poorly known. </plain></SENT>
<SENT sid="271" pm="."><plain>NF κB and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathway are involved in cancer development and progression, in various carcinomas including ovarian cancer, breast cancer, endometrial cancer, cervical cancer [17-23]. </plain></SENT>
<SENT sid="272" pm="."><plain>In human ovarian carcinoma, there is constitutive activation of NF-κB, which leads to uncontrolled growth, anti-apoptosis, and immune evasion [24]. </plain></SENT>
<SENT sid="273" pm="."><plain>In this study, we found that ectopic expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer cells increased NF-κB activity. </plain></SENT>
<SENT sid="274" pm="."><plain>In contrast, downregulation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer decreased NF-κB activity, especially the <z:uniprot sup="inside" fb="2" ids="E1QC64,P0CJ81,P41823,P21521,P48018,P47191,P21579,P46096,P21707,Q9H4A3">p65</z:uniprot> and <z:uniprot sup="inside" fb="7" ids="P83939,P23061,Q05894,Q28618">p50</z:uniprot> subunits of NF-kB protein. </plain></SENT>
<SENT sid="275" pm="."><plain>NF-kB <z:uniprot sup="inside" fb="2" ids="E1QC64,P0CJ81,P41823,P21521,P48018,P47191,P21579,P46096,P21707,Q9H4A3">p65</z:uniprot> is the major subunit involved in ovarian cancer development and progression [25]. </plain></SENT>
<SENT sid="276" pm="."><plain>In our experiments, the silencing of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in ovarian cancer reduced <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> and <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> protein levels; ectopic expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer increased the protein level of <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> and <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot>. </plain></SENT>
<SENT sid="277" pm="."><plain>We also observed that upregulation <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer A2780 cells promoted the <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> and <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> translocation to the nucleus; downregulation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer SKOV3 cells inhibited <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> and <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> translocation to the nucleus. </plain></SENT>
<SENT sid="278" pm="."><plain>To further study the relation between <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> and NF kB, we tried inhibiting NF kB with PDTC (Ammonium pyrrolidinedithiocarbamate), <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> siRNA or/and <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> siRNA. </plain></SENT>
<SENT sid="279" pm="."><plain>We found that PDTC, <z:uniprot sup="inside" fb="7" ids="Q67473,Q05815,P18162,O39164,P22166,O39163,P22176,Q91QZ8,Q43731,P38644">P50</z:uniprot> siRNA or/and <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> siRNA significantly reduced the mRNA and protein level of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>. </plain></SENT>
<SENT sid="280" pm="."><plain>This suggested that NF kB can regulate the expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer. </plain></SENT>
<SENT sid="281" pm="."><plain>Our data indicated that NF kB interaction with <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> was crucial for the progress of ovarian cancer. </plain></SENT>
</text></p><p><text><SENT sid="282" pm="."><plain>Elevation of <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> in the cytosol and the nucleus can occur independently through various pathways [25, 26]. </plain></SENT>
<SENT sid="283" pm="."><plain>Furthermore, <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> is a central factor in canonical Wnt signaling [27]. </plain></SENT>
<SENT sid="284" pm="."><plain>We found that ectopic expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer A2780 cells increased the expression of <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> in the cytoplasm and promote its translocation to the nucleus. </plain></SENT>
<SENT sid="285" pm="."><plain>Downregulation of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer SKOV3 cells decreased the expression of <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> in the cytoplasm and repressed its translocation to the nucleus. </plain></SENT>
<SENT sid="286" pm="."><plain>These results confirmed that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> promoted <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> translocation to the nucleus in ovarian cancer cells. </plain></SENT>
<SENT sid="287" pm="."><plain>Once within the nucleus, <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> regulates expression of genes involved in the activation of the Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> signaling pathway, including sp5, <z:uniprot sup="inside" fb="0" ids="P27782">lef1</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q17103">c-myc</z:uniprot>. </plain></SENT>
<SENT sid="288" pm="."><plain>We had shown that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> upregulated <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot>, therefore, to test whether <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> may also be implicated in regulating the Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathway, we investigated its regulatory effect on TopFlash reporter activity, sp5, <z:uniprot sup="inside" fb="0" ids="P27782">lef1</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q17103">c-myc</z:uniprot>. </plain></SENT>
<SENT sid="289" pm="."><plain>Our results showed that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> mediated TopFlash reporter activity and expression of sp5, <z:uniprot sup="inside" fb="0" ids="P27782">lef1</z:uniprot>, and <z:uniprot sup="inside" fb="0" ids="Q17103">c-myc</z:uniprot> mRNA. </plain></SENT>
<SENT sid="290" pm="."><plain>Based on these findings, we concluded that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> participated in Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> signaling in human ovarian cancer cells. </plain></SENT>
</text></p><p><text><SENT sid="291" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> involved in Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathway and intercellular adhesion, which is causally correlated with the existence of <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot> and catenin complexes. </plain></SENT>
<SENT sid="292" pm="."><plain>The adhesive properties of <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot> correlated with the junctions with <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot>. </plain></SENT>
<SENT sid="293" pm="."><plain>In cancer cells, it plays an important role in cell signaling due to the Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> signaling pathway, which impedes <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> degradation in the cytoplasm, resulting in protein accumulation and transport to the cell nucleus to activate the transcription of many genes [12, 13]. </plain></SENT>
<SENT sid="294" pm="."><plain>The results of this study showed that ectopic expression of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer A2780 cells reduced the protein levels of <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot>. </plain></SENT>
<SENT sid="295" pm="."><plain>In contrast, silencing of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression in ovarian cancer SKOV3 cells significantly increased the protein level of <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot>. </plain></SENT>
<SENT sid="296" pm="."><plain>It indicates that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> reduced <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot> to promote <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> transport to the cell nucleus. </plain></SENT>
</text></p><p><text><SENT sid="297" pm="."><plain>MicroRNA-101 is decreased in epithelial ovarian cancer compared with normal tissue. </plain></SENT>
<SENT sid="298" pm="."><plain>MiR-101 ectopic expression in epithelial ovarian cancer cell lines resulted in increased apoptosis, decreased cellular proliferation, invasiveness, and reduced growth of tumor xenografts [28, 29]. </plain></SENT>
<SENT sid="299" pm="."><plain>Our results showed that miR-101 mimics reduced the mRNA and protein level of <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> in ovarian cancer SKOV3 cells. </plain></SENT>
<SENT sid="300" pm="."><plain>We further confirmed miR-101 inhibited <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> expression by targeting its mRNA 3′UTR. </plain></SENT>
</text></p><p><text><SENT sid="301" pm="."><plain>In conclusion, this study confirms that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> is a tumor promoting gene in humans with ovarian cancer, which was involved in NFkB and Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">β-catenin</z:uniprot> pathway (Fig. </plain></SENT>
<SENT sid="302" pm="."><plain>S2C). </plain></SENT>
<SENT sid="303" pm="."><plain>This also suggests that <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> may be a potential therapeutic target in patients with epithelial ovarian cancer. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s4"><title><text><SENT sid="304" pm="."><plain>MATERIALS AND METHODS </plain></SENT>
</text></title><sec id="s4_1"><title><text><SENT sid="305" pm="."><plain>Tissue specimens </plain></SENT>
</text></title><p><text><SENT sid="306" pm="."><plain>The tissue microarray slides containing malignant and benign ovarian tissues (n=158) were obtained from US Biomax Inc cancer tissue bank collection (US Biomax Inc., MD, USA). </plain></SENT>
<SENT sid="307" pm="."><plain>The Ethics Committee of the Chongqing Medical University approved the study documents and the use of archived cancer tissues. </plain></SENT>
<SENT sid="308" pm="."><plain>All patients provided a written informed consent. </plain></SENT>
</text></p></sec><sec id="s4_2"><title><text><SENT sid="309" pm="."><plain>Cell culture, transfection procedure, and reagents </plain></SENT>
</text></title><p><text><SENT sid="310" pm="."><plain>SKOV3 human ovarian cancer cell line derived from the ascites from a 64 year old caucasian female with an ovarian tumor. </plain></SENT>
<SENT sid="311" pm="."><plain>The A2780 cell line was established from tumor tissue from an untreated patient. </plain></SENT>
<SENT sid="312" pm="."><plain>The ES-2 cell line was established from a surgical tumor specimen taken from a 47 year old black woman. </plain></SENT>
<SENT sid="313" pm="."><plain>CAOV-3 human ovarian cancer cell line derived from a 54 years old caucasian female with ovarian adenocarcinoma. </plain></SENT>
<SENT sid="314" pm="."><plain>The COC1 cell line was derived from the ascites of patients with poorly differentiated ovarian cancer. </plain></SENT>
<SENT sid="315" pm="."><plain>Cisplatin-resistant COC1/<z:uniprot sup="inside" fb="16" ids="O60220">DDP</z:uniprot>, which is derived from its parental ovarian cancer cell line COC1 by stepwise selection in vitro using cisplatin. </plain></SENT>
<SENT sid="316" pm="."><plain>Human ovarian cancer cells were cultured in Rosewall Park Memorial Institute (RPMI) 1640 medium, containing 10% fetal bovine serum and antibiotics, and incubated in an atmosphere with 5% carbon dioxide at 37°C. </plain></SENT>
<SENT sid="317" pm="."><plain>Double-strand oligonucleotides corresponding to the target sequences were synthesized by Genepharma Co., Ltd. </plain></SENT>
<SENT sid="318" pm="."><plain>(Shanghai, China). </plain></SENT>
<SENT sid="319" pm="."><plain>The following sequences were targeted for human <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>, NF-Kb <z:uniprot sup="inside" fb="7" ids="P83939,P23061,Q05894,Q28618">p50</z:uniprot>, and NF-kB <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot> small interfering RNA (siRNA), respectively. </plain></SENT>
<SENT sid="320" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>-1:5′-GCACUUGGGAGUAAUUUGA-3′; <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>-2:5′-GCACACGUGUCCGAUUUAU-3′; NF-Kb <z:uniprot sup="inside" fb="7" ids="P83939,P23061,Q05894,Q28618">p50</z:uniprot>: 5′- GATTGAGGAGAAACGTAAA-3′; NF-Kb <z:uniprot sup="inside" fb="2" ids="E1QC64,P0CJ81,P41823,P21521,P48018,P47191,P21579,P46096,P21707,Q9H4A3">p65</z:uniprot>:5′-GTCACTCTAACGTATGCAA-3′ and NC (negative control) siRNA: 5′-UUCUUCGAAGGUGUCACGUTT-3′. </plain></SENT>
<SENT sid="321" pm="."><plain>Lentiviral vector expressing shRNA targeting <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> (named LV3- shMarch7-1 and LV3-shMarch7-2) and <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>-lentiviral expression vector (named LV5-<z:uniprot sup="inside" fb="0" ids="Q9WV66,Q5XI50">March7</z:uniprot>) were provided from Genepharma Co., Ltd. </plain></SENT>
<SENT sid="322" pm="."><plain>(Shanghai, China). </plain></SENT>
<SENT sid="323" pm="."><plain>miR-101 Mimics (sense: 5′-UACAGUACUGUGAUAACUGAA-3′) were synthesized at Ruibo Biotech (Ruibo Biotechnology, Guangzhou, China). </plain></SENT>
</text></p></sec><sec id="s4_3"><title><text><SENT sid="324" pm="."><plain>Immunohistochemistry </plain></SENT>
</text></title><p><text><SENT sid="325" pm="."><plain>Immunohistochemistry (IHC) was performed according to the SP kit instructions (SP-9000, ZSGB-BIO, Beijing, China). </plain></SENT>
<SENT sid="326" pm="."><plain>After dewaxing and hydration, the sections were heated in citrate buffer (pH 6.0, Sigma-Aldrich, USA) in a microwave oven for 20 minutes for antigen retrieval. </plain></SENT>
<SENT sid="327" pm="."><plain>Further, the sections were cooled naturally to room temperature. </plain></SENT>
<SENT sid="328" pm="."><plain>The sections were washed thrice for 3 minutes per cycle. </plain></SENT>
<SENT sid="329" pm="."><plain>Subsequently, the sections were incubated in 3% aquae hydrogenii dioxidi for 15 minutes at room temperature, and washed thrice with phosphate buffered saline (PBS) for 3 minutes per cycles. </plain></SENT>
<SENT sid="330" pm="."><plain>The sections were blocked with 5% donkey serum (ab7475 Abcam Company) for 30 minutes at 37°C. </plain></SENT>
<SENT sid="331" pm="."><plain>Anti-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> rabbit polyclonal antibody (1:100, bs-9341R, Bioss, Beijing, China) was incubated with the sections overnight at 4°C. </plain></SENT>
<SENT sid="332" pm="."><plain>Negative controls included omission of primary antibody and use of irrelevant primary antibodies. </plain></SENT>
<SENT sid="333" pm="."><plain>The corresponding secondary antibodies that were conjugated to horseradish <z:uniprot sup="inside" fb="71" ids="Q55080,Q05855,Q01603,B3EWG7,P16147,P15984,P28313,A8NK72,P28314,P84714,P85317,P85957,Q9SCX8">peroxidase</z:uniprot> (Bioss Biotechnology) were incubated with the sections for an hour at room temperature. </plain></SENT>
<SENT sid="334" pm="."><plain>The sections were washed thrice in PBS for 3 minutes per cycle. </plain></SENT>
<SENT sid="335" pm="."><plain>The sections were incubated in horseradish enzyme-labeled chain <z:uniprot sup="inside" fb="1" ids="P02701">avidin</z:uniprot> solution (Bioss Biotechnology) for 30 minutes at 37°C, and washed in PBS for 3 minutes x3 cycles. </plain></SENT>
<SENT sid="336" pm="."><plain>The proteins were visualized by diaminobenzidine. </plain></SENT>
<SENT sid="337" pm="."><plain>All the sections were observed by 3 independent pathologists using a light microscope. </plain></SENT>
<SENT sid="338" pm="."><plain>The staining data were obtained from manually recorded reports. </plain></SENT>
<SENT sid="339" pm="."><plain>Staining intensity was graded on a 0–3 scale as follows: 0 (absence of staining), 1 (weakly stained), 2 (moderately stained), and 3 (strongly stained). </plain></SENT>
<SENT sid="340" pm="."><plain>The percentage of positive tumor cells was scored as follows: 0 (absence of tumor cells), 1 (&lt;33% tumor cells), 2 (33–66% tumor cells) and 3 (&gt;66% tumor cells). </plain></SENT>
<SENT sid="341" pm="."><plain>Immunohistochemical score (ranging from 0 to 9) was calculated by multiplying the intensity score and the percentage score [30]. </plain></SENT>
</text></p></sec><sec id="s4_4"><title><text><SENT sid="342" pm="."><plain>Quantitative real-time polymerase chain reaction (PCR) </plain></SENT>
</text></title><p><text><SENT sid="343" pm="."><plain>Total RNA was isolated using an RNA pure High-purity Total RNA Rapid Extraction Kit (BioTeke, RP1201, China), as per the instructions provided in the kit. </plain></SENT>
<SENT sid="344" pm="."><plain>cDNA was synthesized using the iSCRIPT cDNA synthesis kit (Bio-Rad). </plain></SENT>
<SENT sid="345" pm="."><plain>The primers used for amplifying <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>, sp5, <z:uniprot sup="inside" fb="0" ids="P27782">lef1</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="Q17103">c-myc</z:uniprot> and <z:uniprot sup="inside" fb="1" ids="P09124,P53429,O34425,P25858,Q0J8A4,Q7FAH2,Q6K5G8,P25861,P50321,Q01558,P26518,P26519,P26520,P26521,P10097,O96423,Q27890,P22512,P22513,P50322,Q9YFS9,Q9HFX1,P55071,O67161,O28542,Q757I2,Q12552,Q9HGY7,P24750,P34783,P15115,Q59199,P23722,Q00640,Q00301,P46795,P46796,P10096,P48812,P57384,Q07234,Q89AK1,Q92211,Q28259,P70685,P00356,Q9PJN6,Q9Z7T0,B0B879,P0CE13,P24748,Q00584,O52631,Q59309,P29497,Q1DTF9,P28844,Q8J1H3,P35143,O57479,P54117,Q01651,Q05025,P17244,P0CN75,P0CN74,P19089,Q9Y796,Q5XJ10,Q6BMK0,Q94469,Q01597,Q27652,P0A9B3,P20445,B7LQ20,P0C8Z1,Q9N2D5,P00362,Q4U3L0,P44304,Q5V061,B0R2M2,Q9HSS7,Q48335,Q9ZKT0,P55971,P00357,P04406,P87197,A2BLC6,P80534,Q59800,P24163,P24164,O32755,P55070,P52987,Q9UR38,Q92243,Q9N655,O57672,P51640,A6UUN9,A7IB57,P19314,Q12XM4,P10618,P19315,Q2FNA2,Q58546,P58839,A4FZL2,A9A6M9,A6VIW4,Q8PTD3,A3CYG8,Q6M0E6,A5ULT9,A4YHA5,Q2NEN0,O27090,A6URW1,P53430,P16858,A3FKF7,P94915,P64179,A0A0H3MAB5,P47543,P46713,P75358,A0QWW2,P9WN82,P9WN83,P83601,Q3IUT3,P54118,O59841,Q8TFJ2,O42259,O01360,P56649,Q8X1X3,Q5R2J2,Q01982,Q9P8C0,O13507,P26988,Q92263,Q6L125,P00355,Q9UW96,P32637,Q5RAB4,P27726,P24751,Q9V1P1,Q8ZWK7,A4WIW2,A3MTU1,P61879,O59494,A1RV79,B1YD06,P61880,P46406,P52694,P04797,Q8NK47,P29272,P39460,P0A1P1,P0A1P0,P32638,P20287,Q96US8,P24166,P24753,Q28554,I2BA89,P0DJO7,P0A9B5,Q8WZN0,Q4KYY3,P0A038,Q9Z518,Q59906,P0C0G7,P0DB18,Q5XDW3,P68777,P0DB19,P0C0G6,Q4J940,C3N6F0,C4KHW5,C3MQN0,C3MWN0,C3NGT6,C3NEV8,Q971K2,Q9HJ69,P00361,Q5JHB5,P17721,B6YUU0,C6A312,Q97BJ8,O83816,P09317,Q9UVC0,P51009,P51469,Q6CCU7,P08439,P09316">GAPDH</z:uniprot> were synthesized by Guangzhou Funeng Co., Ltd. </plain></SENT>
<SENT sid="346" pm="."><plain>The real-time PCR kit was purchased from Guangzhou Funeng Co., Ltd. </plain></SENT>
<SENT sid="347" pm="."><plain>PCR conditions were 95°C for 10 seconds, 60°C for 20 seconds, 72°C for 10 seconds. </plain></SENT>
<SENT sid="348" pm="."><plain>Each sample was analyzed in triplicates. </plain></SENT>
<SENT sid="349" pm="."><plain>Relative quantification of mRNA was performed using the comparative threshold cycles (CT) method. </plain></SENT>
<SENT sid="350" pm="."><plain>This value was used to plot the gene expression employing the formula 2−Δ ΔCT. </plain></SENT>
</text></p></sec><sec id="s4_5"><title><text><SENT sid="351" pm="."><plain>Detection of protein expression by Western blotting </plain></SENT>
</text></title><p><text><SENT sid="352" pm="."><plain>Expression of NF-kB <z:uniprot sup="inside" fb="7" ids="P83939,P23061,Q05894,Q28618">p50</z:uniprot>, <z:uniprot sup="inside" fb="2" ids="Q49539">P65</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">beta catenin</z:uniprot> protein was analyzed by the Western blot method [9]. </plain></SENT>
<SENT sid="353" pm="."><plain>The primary antibodies used included polyclonal rabbit anti-<z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> (1:1000; ab84130; Abcam Inc., Cambridge, MA, USA); polyclonal rabbit anti-NF-kB <z:uniprot sup="inside" fb="2" ids="E1QC64,P0CJ81,P41823,P21521,P48018,P47191,P21579,P46096,P21707,Q9H4A3">p65</z:uniprot> (1:1000; ab7970; Abcam Inc., Cambridge, MA, USA); polyclonal rabbit anti-NF-kB <z:uniprot sup="inside" fb="7" ids="P83939,P23061,Q05894,Q28618">p50</z:uniprot> (1:1000; ab7971; Abcam Inc., Cambridge, MA, USA); anti-<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">beta catenin</z:uniprot> antibody rabbit polyclonal antibody (1:500, bs-1165R, Bioss, Beijing, China) and polyclonal rabbit anti-<z:uniprot sup="inside" fb="1" ids="P09124,P53429,O34425,P25858,Q0J8A4,Q7FAH2,Q6K5G8,P25861,P50321,Q01558,P26518,P26519,P26520,P26521,P10097,O96423,Q27890,P22512,P22513,P50322,Q9YFS9,Q9HFX1,P55071,O67161,O28542,Q757I2,Q12552,Q9HGY7,P24750,P34783,P15115,Q59199,P23722,Q00640,Q00301,P46795,P46796,P10096,P48812,P57384,Q07234,Q89AK1,Q92211,Q28259,P70685,P00356,Q9PJN6,Q9Z7T0,B0B879,P0CE13,P24748,Q00584,O52631,Q59309,P29497,Q1DTF9,P28844,Q8J1H3,P35143,O57479,P54117,Q01651,Q05025,P17244,P0CN75,P0CN74,P19089,Q9Y796,Q5XJ10,Q6BMK0,Q94469,Q01597,Q27652,P0A9B3,P20445,B7LQ20,P0C8Z1,Q9N2D5,P00362,Q4U3L0,P44304,Q5V061,B0R2M2,Q9HSS7,Q48335,Q9ZKT0,P55971,P00357,P04406,P87197,A2BLC6,P80534,Q59800,P24163,P24164,O32755,P55070,P52987,Q9UR38,Q92243,Q9N655,O57672,P51640,A6UUN9,A7IB57,P19314,Q12XM4,P10618,P19315,Q2FNA2,Q58546,P58839,A4FZL2,A9A6M9,A6VIW4,Q8PTD3,A3CYG8,Q6M0E6,A5ULT9,A4YHA5,Q2NEN0,O27090,A6URW1,P53430,P16858,A3FKF7,P94915,P64179,A0A0H3MAB5,P47543,P46713,P75358,A0QWW2,P9WN82,P9WN83,P83601,Q3IUT3,P54118,O59841,Q8TFJ2,O42259,O01360,P56649,Q8X1X3,Q5R2J2,Q01982,Q9P8C0,O13507,P26988,Q92263,Q6L125,P00355,Q9UW96,P32637,Q5RAB4,P27726,P24751,Q9V1P1,Q8ZWK7,A4WIW2,A3MTU1,P61879,O59494,A1RV79,B1YD06,P61880,P46406,P52694,P04797,Q8NK47,P29272,P39460,P0A1P1,P0A1P0,P32638,P20287,Q96US8,P24166,P24753,Q28554,I2BA89,P0DJO7,P0A9B5,Q8WZN0,Q4KYY3,P0A038,Q9Z518,Q59906,P0C0G7,P0DB18,Q5XDW3,P68777,P0DB19,P0C0G6,Q4J940,C3N6F0,C4KHW5,C3MQN0,C3MWN0,C3NGT6,C3NEV8,Q971K2,Q9HJ69,P00361,Q5JHB5,P17721,B6YUU0,C6A312,Q97BJ8,O83816,P09317,Q9UVC0,P51009,P51469,Q6CCU7,P08439,P09316">GAPDH</z:uniprot> (1:1000; AB10016; Sangon Biotech, Shanghai, China). </plain></SENT>
<SENT sid="354" pm="."><plain>The band density was analyzed using a gel imaging system and compared against an internal control. </plain></SENT>
</text></p></sec><sec id="s4_6"><title><text><SENT sid="355" pm="."><plain>Cell proliferation assay </plain></SENT>
</text></title><p><text><SENT sid="356" pm="."><plain>Cell proliferation was determined using the <z:uniprot sup="inside" fb="88" ids="P41520,Q9TS44,Q9PU41,P68125,P06307,P80344,P68126,P23362,P0C229,P09240,O57312,P01356,P01355,Q9PU29,P80345,Q8JHB9">CCK</z:uniprot>-8 assay as described previously [10], and EdU assay was performed using the Cell-Light TM EdU imaging detecting kit according to the instructions in the kit (Ruibo Biotechnology, Guangzhou, China). </plain></SENT>
<SENT sid="357" pm="."><plain>EdU is a thymidine analog that can be used to label cells undergoing DNA replication [11]. </plain></SENT>
</text></p></sec><sec id="s4_7"><title><text><SENT sid="358" pm="."><plain>Colony formation assay </plain></SENT>
</text></title><p><text><SENT sid="359" pm="."><plain>SKOV3 cells infected with LV3-shMarch7-1 or LV3-shMarch7-2, and A2780 cells infected with LV5-<z:uniprot sup="inside" fb="0" ids="Q9WV66,Q5XI50">March7</z:uniprot> were cultured by seeding 1000 cells in 6-well plates, and the number of colonies formed was checked after 2 weeks. </plain></SENT>
<SENT sid="360" pm="."><plain>All experiments were triplicated. </plain></SENT>
</text></p></sec><sec id="s4_8"><title><text><SENT sid="361" pm="."><plain>Dual-<z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> reporter gene assay </plain></SENT>
</text></title><p><text><SENT sid="362" pm="."><plain><z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">Luciferase</z:uniprot> reporter gene assay was performed using the Dual-<z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">Luciferase</z:uniprot> Reporter Assay System (Promega) according to the instructions provided by the manufacturer. </plain></SENT>
<SENT sid="363" pm="."><plain>For <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> 3′ UTR <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> reporter assay, wild type or mutant reporter constructs (termed WT or Mut; purchased from Genepharma Co., Ltd., Shanghai, China) were co-transfected into skov3 cells in 24-well plates with 100 nM miR-101 or 100 nM miR-NC and Renilla plasmid by using Endofectin™-Plus (GeneCopoeia). </plain></SENT>
<SENT sid="364" pm="."><plain>TOPflash reporter plasmid and NF kB reporter plasmids were purchased from Shanghai Qcbio Science &amp; Technologies Co., Ltd. </plain></SENT>
<SENT sid="365" pm="."><plain>(Shanghai, China). </plain></SENT>
<SENT sid="366" pm="."><plain>Reporter gene assay was performed 48 hours post-transfection using the Dual <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">Luciferase</z:uniprot> Assay System (Promega, Madison, WI). </plain></SENT>
<SENT sid="367" pm="."><plain>Firefly <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity was normalized for transfection efficiency using the corresponding Renilla <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity. </plain></SENT>
<SENT sid="368" pm="."><plain>All experiments were performed at least 3 times. </plain></SENT>
</text></p></sec><sec id="s4_9"><title><text><SENT sid="369" pm="."><plain>Wound healing assay and Matrigel invasion assays </plain></SENT>
</text></title><p><text><SENT sid="370" pm="."><plain>Migration of SKOV3 and A2780 cells were analyzed using the wound-healing assay in vitro. </plain></SENT>
<SENT sid="371" pm="."><plain>Cells were seeded into 6-well plates and cultivated until 90% growth confluence. </plain></SENT>
<SENT sid="372" pm="."><plain>Wounds were afflicted by scraping the monolayer cells with a sterile pipette tip. </plain></SENT>
<SENT sid="373" pm="."><plain>At 0, 24, 48 and 72 hours after the wounding, cells were observed under low power in an Olympus light microscope. </plain></SENT>
<SENT sid="374" pm="."><plain>The distance between the 2 wounds were measured at each time point, and expressed as the average percent of wound closure as compared to that at zero time. </plain></SENT>
<SENT sid="375" pm="."><plain>Invasion of SKOV3 and A2780 cells were evaluated by Matrigel invasion assays. </plain></SENT>
<SENT sid="376" pm="."><plain>For Transwell invasion assays, the upper side of an 8 μm pore, 6.5-mm polycarbonate transwell filter (Corning, New York, NY) chamber was uniformly coated with Matrigel basement membrane matrix (BD Biosciences, Bedford, MA) for 2 h at 37°C before the cells were added. </plain></SENT>
<SENT sid="377" pm="."><plain>A total of 5×104 cells were seeded into the top chamber of a trans-well filter (in triplicate) and incubated for 48 hours. </plain></SENT>
<SENT sid="378" pm="."><plain>Invasive cells on the lower side of the filter, were fixed in 4% paraformaldehyde, stained in 0.5% crystal violet (Beyotime), and counted using a microscope. </plain></SENT>
<SENT sid="379" pm="."><plain>A total of 5 fields were counted for each transwell filter. </plain></SENT>
<SENT sid="380" pm="."><plain>Each field was counted and photographed at 200× magnification. </plain></SENT>
</text></p></sec><sec id="s4_10"><title><text><SENT sid="381" pm="."><plain>In vivo tumor xenograft study </plain></SENT>
</text></title><p><text><SENT sid="382" pm="."><plain>All procedures for animal experiments were approved by the Committee on the Use and Care on Animals (Chongqing Medical University, Chongqing, China), and performed in accordance with the institution guidelines. </plain></SENT>
<SENT sid="383" pm="."><plain>Ovarian cancer SKOV3 or A2780 cells were infected with indicated lentiviral vectors and injected (5×106 cells per mouse in 200 ul) subcutaneously into the left armpit of 6-week-old BALB/c nude mice. </plain></SENT>
<SENT sid="384" pm="."><plain>21 days later, animals were sacrificed to confirm the presence of tumors and weigh the established tumors. </plain></SENT>
</text></p></sec><sec id="s4_11"><title><text><SENT sid="385" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="386" pm="."><plain>All statistical analyses were performed using SPSS software, version 17.0 (Chicago, IL). </plain></SENT>
<SENT sid="387" pm="."><plain>Each experiment was performed in triplicates. </plain></SENT>
<SENT sid="388" pm="."><plain>Statistical analysis was performed by Student's t-test or analysis of variance (ANOVA). </plain></SENT>
<SENT sid="389" pm="."><plain>The chi-square test was used to compare the associations between <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> overexpression and clinicopathologic variables of EOC samples. </plain></SENT>
<SENT sid="390" pm="."><plain>Data were presented as Mean ± standard deviation. </plain></SENT>
<SENT sid="391" pm="."><plain>Statistical significance was defined as a p-value less than 0.05. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s5"><title><text><SENT sid="392" pm="."><plain>SUPPLEMENTARY MATERIAL, FIGURES </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-06-12174-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e1105" position="anchor"/></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="393" pm="."><plain>We thank members of our laboratory for technical help and stimulating discussions. </plain></SENT>
<SENT sid="394" pm="."><plain>This work was supported by grants from the Natural Science Foundation of Chongqing (CSTC 2012JJB10030), the National Science Foundation of China Grants 81172492. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><SecTag type="COMP_INT"><fn fn-type="conflict"><p><text><SENT sid="395" pm="."><plain>Conflicts of Interest </plain></SENT>
</text></p><p><text><SENT sid="396" pm="."><plain>There are no potential conflicts of interest to declare. </plain></SENT>
</text></p></fn></SecTag></fn-group><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="R1"><text><SENT sid="397" pm="."><plain>1SerralboOMarcelleCMigrating cells mediate long-range WNT signalingDevelopment (Cambridge, England)2014141205763 </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="398" pm="."><plain>2NathanJASenguptaSWoodSAAdmonAMarksonGSandersonCLehnerPJThe <z:uniprot sup="inside" fb="2" ids="P69310,Q865C5,P68197,P19848,Q8SWD4,P69313,P84589,P69317,P62975,P69326">ubiquitin</z:uniprot> E3 ligase <z:uniprot sup="inside" fb="0" ids="Q9H992,Q5R9W2">MARCH7</z:uniprot> is differentially regulated by the deubiquitylating enzymes <z:uniprot sup="inside" fb="0" ids="Q6U7I1,Q93009">USP7</z:uniprot> and USP9XTraffic (Copenhagen, Denmark)20089113045 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="399" pm="."><plain>3MuthukumaranaPALyonsGEMiuraYThompsonLHWatsonTGreenCJShureySHessADRosengardBRMetcalfeSMEvidence for functional inter-relationships between <z:uniprot sup="inside" fb="0" ids="Q9BZS1,Q6U8D7">FOXP3</z:uniprot>, leukaemia inhibitory factor, and <z:uniprot sup="inside" fb="0" ids="Q9H992,Q9WV66">axotrophin</z:uniprot>/MARCH-7 in transplantation toleranceInt Immunopharmacol200661993200117161353 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="400" pm="."><plain>4SzigyartoCASibbonsPWilliamsGUhlenMMetcalfeSMThe E3 ligase <z:uniprot sup="inside" fb="0" ids="Q9H992,Q9WV66">axotrophin</z:uniprot>/MARCH-7: protein expression profiling of human tissues reveals links to adult stem cellsThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society201058301819901269 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="401" pm="."><plain>5FeldnerJCBrandtBHCancer cell motility--on the road from <z:uniprot sup="inside" fb="0" ids="P04412">c-erbB</z:uniprot>-2 receptor steered signaling to <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> reorganizationExp Cell Res20022729310811777334 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="402" pm="."><plain>6MaccioAMadedduCInflammation and ovarian cancerCytokine2012581334722349527 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="403" pm="."><plain>7SchauerIGZhangJXingZGuoXMercado-UribeISoodAKHuangPLiuJInterleukin-1beta promotes ovarian tumorigenesis through a <z:uniprot sup="inside" fb="117" ids="Q9W678,O93379,P25035,P79820,O12946,Q9W679,O57538,Q92143">p53</z:uniprot>/NF-kappaB-mediated inflammatory response in stromal fibroblastsNeoplasia (New York, N.Y.)20131540920 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="404" pm="."><plain>8LiuCZZhangLChangXHChengYXChengHYYeXFuTYChenJCuiHOverexpression and immunosuppressive functions of transforming <z:uniprot sup="inside" fb="0" ids="Q8V307,Q776B5,P08072,Q6RZT5,P08441">growth factor</z:uniprot> 1, vascular endothelial <z:uniprot sup="inside" fb="0" ids="Q8V307,Q776B5,P08072,Q6RZT5,P08441">growth factor</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P43480,Q2PE73,Q0Z972,P48411,Q9Z1Y5,P46651,P51746,Q6A2H4,P55029,Q28374,P22301,Q865X4,P79338,P51496,P51497,Q9JHK7,P47965,P18893,O46673,A2T6Z6,Q5Q0V6,Q29055,Q9TSJ4,P29456,Q8MKG9,Q29408,O97798,Q25BC1">interleukin-10</z:uniprot> in epithelial ovarian cancerChin J Cancer Res201224130723359769 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="405" pm="."><plain>9WuHLiZYangPZhangLFanYLiZPKM2 depletion induces the compensation of glutaminolysis through <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">beta-catenin</z:uniprot>/<z:uniprot sup="inside" fb="0" ids="Q17103">c-Myc</z:uniprot> pathway in tumor cellsCell Signal2014 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="406" pm="."><plain>10DuntyWCJrKennedyMWChalamalasettyRBCampbellKYamaguchiTPTranscriptional profiling of <z:uniprot sup="inside" fb="0" ids="P27467">Wnt3a</z:uniprot> mutants identifies Sp transcription factors as essential effectors of the Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">beta-catenin</z:uniprot> pathway in neuromesodermal stem cellsPLoS One20149e8701824475213 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="407" pm="."><plain>11WangSDongYZhangYWangXXuLYangSLiXDongHXuLSuLNgSSChangZSungJJDACT2 is a functional tumor suppressor through inhibiting Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">beta-catenin</z:uniprot> pathway and associated with poor survival in colon cancerOncogene20140 </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="408" pm="."><plain>12RossoMLapyckyjLAmianoNBessoMJSanchezMChuluyanEVazquez-LevinMHSecretory Leukocyte <z:uniprot sup="inside" fb="0" ids="P84885,P26228,P43131,P61153,P0DM47">Protease Inhibitor</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="P03973,P22298,Q6V9X0,P61153">SLPI</z:uniprot>) Expression Downregulates <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-Cadherin</z:uniprot>, Induces <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">beta-catenin</z:uniprot> Re-Localization and Triggers Apoptosis-Related Events in Breast Cancer CellsBiology of the cell / under the auspices of the European Cell Biology Organization2014 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="409" pm="."><plain>13PiaoHLYuanYWangMSunYLiangHMaLalpha-catenin acts as a tumour suppressor in <z:uniprot sup="inside" fb="0" ids="Q24298,Q6R8F2,F1PAA9,P08641,P12830,P09803,Q5RAX1,Q9R0T4,P30944">E-cadherin</z:uniprot>-negative basal-like breast cancer by inhibiting NF-kappaB signallingNat Cell Biol2014162455424509793 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="410" pm="."><plain>14WilsonALSchrecengostRSGuerreroMSThomasKSBoutonAHBreast cancer antiestrogen resistance 3 (<z:uniprot sup="inside" fb="0" ids="Q58DL5,O75815,Q4R8R1">BCAR3</z:uniprot>) promotes cell motility by regulating <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> cytoskeletal and adhesion remodeling in invasive breast cancer cellsPLoS One20138e6567823762409 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="411" pm="."><plain>15CoughlinMFBielenbergDRLenormandGMarinkovicMWaghorneCGZetterBRFredbergJJCytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potentialClin Exp Metastasis2013302375022961212 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="412" pm="."><plain>16YaoYGuXLiuHWuGYuanDYangXSongYMetadherin regulates proliferation and metastasis via <z:uniprot sup="inside" fb="72" ids="Q05214,P53491,P26182,P53455,Q75D00,Q2U7A3,O13419,P90689,Q92192,P14235,Q9UVZ8,P60009,P80709,P53498,P53499,O65315,Q9UVX4,P30161,O17320,Q92193,P48465,P26183,P53500,Q24733,Q8SWN8,P11426,Q8X119,P53502,Q39758,Q6TCF2,P51775,O81221,Q99023,P17128,Q9P4D1,P45520,P91754,O16808,O65316,P78711,O74258,Q39596,P53689,P13363,A5DQP9,P24902,P81085,P45521,P50138,P60011,O65314,P10989,Q11212,O00937,P68555,P10365,P53476,P53477,P20904,Q9UVF3,P60010">actin</z:uniprot> cytoskeletal remodelling in non-small cell lung cancerBr J Cancer20141113556424918821 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="413" pm="."><plain>17UnoMSaitohYMochidaKTsuruyamaEKiyonoTImotoIInazawaJYuasaYKubotaTYamaokaSNF-kappaB inducing kinase, a central signaling component of the non-canonical pathway of NF-kappaB, contributes to ovarian cancer progressionPLoS One20149e8834724533079 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="414" pm="."><plain>18RayPStacerACFennerJCavnarSPMeguiarKBrownMLukerKELukerGDCXCL12-gamma in primary tumors drives breast cancer metastasisOncogene20140 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="415" pm="."><plain>19OhJHKimJHAhnHJYoonJHYooSCChoiDSLeeISRyuHSMinCKSyndecan-1 enhances the endometrial cancer invasion by modulating <z:uniprot sup="inside" fb="0" ids="P52176,O18733,P14780,P41245,P41246,P50282">matrix metalloproteinase-9</z:uniprot> expression through nuclear factor kappaBGynecol Oncol20091145091519539355 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="416" pm="."><plain>20SinghMSinghRBhuiKTyagiSMahmoodZShuklaYTea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor-kappaB and <z:uniprot sup="inside" fb="10" ids="Q8INB9,P31750">Akt</z:uniprot> activation in human cervical cancer cellsOncol Res2011192455721776820 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="417" pm="."><plain>21ZhangPLiHYangBYangFZhangLLKongQYChenXYWuMLLiuJBiological significance and therapeutic implication of resveratrol-inhibited Wnt, <z:uniprot sup="inside" fb="141" ids="P46530">Notch</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> signaling in cervical cancer cellsGenes Cancer201451546425061499 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="418" pm="."><plain>22ZhaoYYangYTrovikJSunKZhouLJiangPLauTSHoivikEASalvesenHBSunHWangHA Novel Wnt Regulatory Axis in Endometrioid Endometrial CancerCancer Res2014 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="419" pm="."><plain>23WangZWangNLiWLiuPChenQSituHZhongSGuoLLinYShenJChenJCaveolin-1 mediates chemoresistance in breast cancer stem cells via <z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">beta-catenin</z:uniprot>/<z:uniprot sup="inside" fb="0" ids="Q4GZT4,Q9UNQ0,Q5MB13,Q8MIB3">ABCG2</z:uniprot> signaling pathwayCarcinogenesis2014 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="420" pm="."><plain>24ClaussANgVLiuJPiaoHRussoMVenaNShengQHirschMSBonomeTMatulonisULigonAHBirrerMJDrapkinROverexpression of <z:uniprot sup="inside" fb="0" ids="P19957,Q29125">elafin</z:uniprot> in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survivalNeoplasia (New York, N.Y.)20101216172 </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="421" pm="."><plain>25Ataie-KachoiePBadarSMorrisDLPourgholamiMHMinocycline targets the NF-kappaB Nexus through suppression of TGF-beta1-<z:uniprot sup="inside" fb="0" ids="O43318,P49116,P43565">TAK1</z:uniprot>-IkappaB signaling in ovarian cancerMol Cancer Res20131112799123858099 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="422" pm="."><plain>26ArendRCLondono-JoshiAISamantRSLiYConnerMHidalgoBAlvarezRDLandenCNStraughnJMBuchsbaumDJInhibition of Wnt/<z:uniprot sup="inside" fb="0" ids="Q0VCX4,B6V8E6,F1QGH7,P35222,Q02248,Q9WU82,P26233,P35223,P35224">beta-catenin</z:uniprot> pathway by niclosamide: a therapeutic target for ovarian cancerGynecol Oncol20141341122024736023 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="423" pm="."><plain>27MacDonaldBTTamaiKHeXWnt/beta-catenin signaling: components, mechanisms, and diseasesDev Cell20091792619619488 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="424" pm="."><plain>28SemaanAQaziAMSewardSChamalaSBryantCSKumarSMorrisRSteffesCPBouwmanDLMunkarahARWeaverDWGruberSABatchuRBMicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of <z:uniprot sup="inside" fb="14" ids="O19002,P38936,P39689,Q07828,P50633,P50634,Q62092,Q08545,P61585,P63028,Q11118">p21</z:uniprot>(waf(1)/cip(1))Pharm Res20112830799021818714 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="425" pm="."><plain>29IorioMVVisoneRDiLGDonatiVPetroccaFCasaliniPTaccioliCVoliniaSLiuCGAlderHCalinGAMénardSCroceCMMicroRNA signatures in human ovarian cancerCancer Res200767869970717875710 </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="426" pm="."><plain>30AuCWSiuMKLiaoXWongESNganHYTamKFChanDCChanQKCheungANTyrosine kinase B receptor and <z:uniprot sup="inside" fb="0" ids="Q1X706,Q1X702,O97759,Q6LCI5,Q1X700,Q1HN40,Q1X708,Q95106,Q1X6Z7,Q1X707,Q7YRB4,O70183,Q1X6Z6,P25429,Q1HN42,Q1X711,Q1X701,Q90322,Q1X710,Q1HN34,Q1X6Z8,Q1HN32,Q1HN36,Q1X709,Q1X704,Q9TST3,O18753,Q0EAB7,P23560,Q1HN31,Q49M28,Q1HN33,P25431,Q06225,Q1X703,P21237,Q5IS78,P14082,O18755,Q8QG74,P25430,Q1X6Z5,P23363,Q1X705,Q4L0Y3,Q1X6Z9,O18752,Q3SAT7,P25432,Q1HN38,Q02193">BDNF</z:uniprot> expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcomeCancer Lett20092811516119307055 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
